Malignant neoplasm of large intestine

LONDON , Oct. 9, 2023 /PRNewswire/ -- Colorectal Cancer often referred to as malignant colonic tumor, metastatic bowel cancer, metastatic colon carcinoma, or metastatic colorectal carcinoma, is a type of cancer that begins in the colon or rectum is a form of cancer occurring in the rectum or colon. It is an aggressive form of cancer that can rapidly spread to other parts of the digestive system. There has been an increased pervasiveness of this cancer equally affecting both men and women. Early detection in the form of colonoscopy screening plays a vital role in promoting fast prognosis. Drug development endeavours are also going on across various parts of the world with an aim to find a permanent cure for this ailment. The increased CRC disease burden has become a caused of concern for various nations. It is worth noting that colorectal cancer also known as metastatic rectal cancer usually begins as small, noncancerous growths called polyps on the inner lining of the colon or rectum. The growth of large polyp in colon takes the form of aggressive cancer if not diagnosed at an early stage. The colon is the large intestine, and the rectum is the last section of the colon, leading to the anus. Risk factors for colorectal cancer include age (the risk increases with age), a family history of the disease, certain genetic mutations, a diet high in red and processed meats, obesity, smoking, heavy alcohol consumption, and certain medical conditions such as inflammatory bowel disease (IBD). Price and Market Access The Market Competitors Listed Below are Revolutionizing Healthcare with Innovative Diagnostic Inventions: GI View Ltd Sun Pharmaceuticals Industries Ltd. Exact Sciences Corporation Becton, Dickinson, and Company DiagnoTech Corporation FUJIFILM Holdings America Corporation Cipla Ltd. QIAGEN MANCHESTER LTD Innovia Medical Gastro Diagnostics.Ltd KARL STORZ SE & Co. KG Thyrocare Technologies Epigenomics AG Cardinal Health Inc. Radiance Imaging System HUGER Medical Instrument Co., Ltd Apollo Diagnostics Roche Molecular Systems, Inc. Paramount Surgimed Limited UltraScan diagnostics Pro Scope Systems Fortis Healthcare Illumina, Inc. Integra LifeSciences Med Imaging Solutions MECAN MEDICAL EQUIPMENT CO LTD Epigenomics Ventana Medical Systems KAI Group Mindray Medical International Limited Others Learn More About the FDA NDA & BLA Approval (NME) Drugs for Colorectal Cancer @ DiseaseLandscape Insights has been offering healthcare consulting services to the players operating in this vertical. It is assisting them with clinical trial feasibility analysis, clinical trial management, price and market access, commercial strategy analysis, product portfolio extension, along with other pivotal activities. The industry participants are trying to strengthen their position in the CRC management landscape. Colorectal Cancer Disease Overview- Types, Causes, and Symptoms: Adenocarcinoma, Carcinoid Tumors, Gastrointestinal Stromal Tumors (GISTs), Lymphomas, and Sarcomas are the primary types of CRC. Although the exact causes behind its occurrence has not been known but genetic issues, age, unhealthy lifestyle, smoking, and alcohol intake, can be the triggering factors. The major symptoms are anemia, fatigue, weakness, blood in stool, changes in bowel habits, abdominal discomfort, and weight loss. Early detection can be life saving for patients. The diagnostic landscape of this disease is diverse wherein colonoscopy recommendations are given by doctors due to its accuracy. Colonoscopy screening age is typically 45 to 50 for average-risk individuals. Apart from that ct scan colon cancer and ct scan for bowel cancer, may also be suggested for the detection of colorectal malignant neoplasm. Effective treatment solutions are chemotherapy for colorectal cancer and radiation for rectal cancer. The latter uses high-energy radiation to target and destroy cancer cells in the rectum and can be administered alone or in combination with other treatments. Unlock the Benefits Today! Get Started Now and Elevate Your Experience @ Final Words: CRC is a highly prevalent forms of cancer affected a large part of the global population. It predominantly affects the digestive system specially the rectum, colon, and large intestine. Smoking, excessive alcohol intake, sedentary lifestyle, age, and family history, among others are known to be the factors leading to the onset of this ailment. DLI has been a support system for the players looking forward to transforming the CRC management. It has been assisting them with regulatory consulting, pharma consulting services, post launch strategies, product pipeline assessment, and treatment gaps identification. The sole aim of this health consultant and other players is to save the lives of the patients diagnosed with this devastating ailment. Browse Through More Oncology Diseases Research Reports. Related Reports: Insights and Trends in the Global Landscape of Lung Cancer Services The symptoms, transmission, and precautions of Monkeypox The Myths of Pneumonia: Symptoms, Causes, and Prevention Methods Navigating the Complex Autoimmune Disorder of Lupus Ringworm Comprehensive Guide: Symptoms, Causes, and Treatment Diverticulitis: A Complete Guide to the Symptoms, Causes, and Treatments When it comes to strategic Diabetes Disease consultancy, some of the areas we assist you understand include Regulatory Insights, Disease Landscape, and Market Access Expertise. Find treatments for HPV illness using specialized market entry strategies. FDA/EMA insights and clinical trial advice. Examine right away! Learn about specific approaches to Pancreatic Cancer Disease market access, pricing, and reimbursement. Learn about market research and clinical trials. Change your business immediately. Learn about KOLs, the FDA, epidemiology, price reimbursement, and more in this market report on Anemia Disease. Your trustworthy source for info on anemia. Examine right away! Chlamydia Disease symptoms, treatment, and market research. Keep up with epidemiology research, FDA and EMA updates, and market entry tactics. employing our tried-and-true strategy, penetrate the Ovarian Cancer Disease market. Learn to negotiate the regulatory process, discover the key opinion leaders for your product, and establish fair pricing. Learn about Gastric Cancer Market Strategies, KOL Insights, Regulatory Updates, and Market Intelligence. Make use of our knowledge to get through challenges. The success of the Breast Cancer market is built on FDA insights, pricing strategies, and a successful market launch. Investigate epidemiology and market intelligence to gain a competitive edge. Find out more about Prostate Cancer Consulting, FDA-EMA Drugs, Pricing, and Regulatory Insights. Obtain an epidemiology study and market access. Rely on DLI! FDA-EMA Approved Drugs, Disease Landscape, and Epidemiology Studies: Expert Consulting on Skin Cancer. Pricing Compensation and Market Access. Find out more about Tonsillitis symptoms, consulting services, drug costs, FDA-approved medications, disease landscape, regulatory insights, epidemiology, and price reimbursement. Investigate the epidemiology, prevention, and consulting services for Scrub Typhus. Discover the landscape of diseases, FDA-EMA approved medications, and more. Discover the market insights, competitive environment, regulatory updates, and epidemiology study for lymphoma. Market entry strategy: Unlock market intelligence. About Disease Landscape:  Disease Landscape, a pioneering company specializing in Disease Intelligence, Pricing, and Market Access. Utilizing the power of data analytics, Disease Landscape Insights is dedicated to healthcare sector with invaluable, finely crafted insights and recommendations regarding global pricing and market access strategies. As a specialized firm, we are committed to delivering unparalleled insights into pricing and market access, custom-tailored to the healthcare and pharmaceutical industries. Our data-driven solutions and cutting-edge technology position us as your trustworthy partner, offering swift, adaptable, and evidence-based alternatives to traditional market access and pricing research methods.  Our core competencies encompass Market Research Services, Consulting Services, Global Pricing and Market Access, Epidemiology Studies, as well as Product Portfolio and Pipeline Services. Our expertise lies in furnishing comprehensive data intelligence throughout every phase of drug and device research.  Contact Us:  Disease Landscape Insights LLP  6th Floor, Sr No.207, Office A H 6070 Phase 1  Solitaire Business Hub, Viman Nagar  Pune, Maharashtra, 411014  Email: [email protected] Email: [email protected] Sales: +44-2038074155  Asia Office: +917447409162 Blog:   Case Study:    Pharma consulting Services  Follow Us: LinkedIn | Twitter | Facebook Logo: SOURCE Disease Landscape Insights

Top hospital in Tucson joins Medicare Advantage company’s provider network, elevating senior care for members in Pima, Santa Cruz countiesTUCSON, Ariz. and ORANGE, Calif., July 05, 2023 (GLOBE NEWSWIRE) -- Alignment Health Plan, the award-winning Medicare Advantage plan from Alignment Health, today announced it is expanding access to quality health care and services for its members in Pima and Santa Cruz counties through a new agreement with Tucson Medical Center (TMC). Effective July 1, the agreement will provide Alignment’s Arizona plan members access to approximately 165 providers and TMC services. “By partnering with Tucson Medical Center, our members gain access to more top primary care providers and specialists who share our passion for transforming the lives of seniors,” said Dan Peterson, Arizona market president at Alignment Health. “It’s important to our mission to tap into respected community partners to help seniors live their best lives as we usher in a new era of aging. We’re excited to team up with TMC to provide more care options for the members we serve in Pima and Santa Cruz.” Tucson Medical Center has cared for its community since 1944, serving as Tucson’s locally governed, nonprofit regional hospital for more than 75 years. It was ranked by U.S. News & World Report as the No. 1 hospital in the Tucson metro area for two consecutive years, No. 4 in the state last year and No. 1 in Tucson for pulmonology, nephrology, diabetes, colon cancer surgery, hip replacement and knee replacement for 2022-2023. With more than 600 beds, it is the second-largest hospital in Southern Arizona. Arizona members enrolled in Alignment’s PPO and HMO plans, including its chronic special needs plan for individuals with heart disease or diabetes, will have access to all TMC services, including emergency care, intensive care, cardiac care, orthopedic, neuroscience, hospice, surgical, vascular, geropsychiatric care and more, as well as TMC One, which provides primary and specialty care via a dedicated team of more than 60 primary care providers and dozens of specialists. About Alignment HealthAlignment Health is championing a new path in senior care that empowers members to age well and live their most vibrant lives. A consumer brand name of Alignment Healthcare (NASDAQ: ALHC), Alignment Health is a tech-enabled Medicare Advantage company that offers more than 40 benefits-rich, value-driven plans that serve 52 counties across six states. The company partners with nationally recognized and trusted local providers to deliver coordinated care, powered by its customized care model, 24/7 concierge care team and purpose-built technology, AVAⓇ. Based in California, the company’s mission-focused team makes high-quality, low-cost care a reality for members every day. As it expands its offerings and grows its national footprint, Alignment upholds its core values of leading with a serving heart and putting the senior first. For more information, visit www.alignmenthealth.com. Media ContactPriya ShahmPR, Inc. for Alignment Healthalignment@mpublicrelations.com

Provides option to access capital to support commercial and clinical programsBERKELEY, Calif. and MAINZ, Germany, June 29, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that it has entered into a $50 million Pre-Paid Advance Agreement (PPA) with Yorkville Advisors Global, LP (Yorkville), a global investment management firm. Simultaneously, the Company and Yorkville also entered into a $5.5 million Promissory Note (Note) with approximately $5.0 million funded at closing. “We are executing an ambitious commercial and product development plan, and the flexibility of this funding vehicle enables us to continue operating in this strategic and opportunistic fashion,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. Mainz is currently commercializing its flagship product ColoAlert, a highly efficacious and easy-to-use detection test for colorectal cancer (CRC), across Europe and in select international territories via a differentiated business model of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility. In December of 2022, the Company initiated a U.S. Pivotal Clinical Study (ReconAAsense) for a CRC screening test that may integrate the Company’s portfolio of novel gene expression (mRNA) biomarkers, providing the opportunity to achieve gold standard status in the at-home CRC diagnostic tool market. These biomarkers have demonstrated the potential to identify advanced adenomas, a type of curable pre-cancerous polyp often attributed to CRC, which is being evaluated in European and U.S. studies (ColoFuture/eAArly DETECT). Results from both studies are expected in 2023, and Mainz anticipates enrollment in ReconAAsense to commence in the second half of 2023. The Company’s early-stage product development pipeline is highlighted by PancAlert, a potential first-in-class screening test for pancreatic cancer. For further details on the transaction, please see the Company’s Form 6-K that has been filed with the Securities and Exchange Commission by visiting www.SEC.gov. About ColoAlert®ColoAlert®, Mainz Biomed’s flagship product, delivers high sensitivity and specificity in a user-friendly, at-home colorectal cancer (CRC) screening kit. This non-invasive test can be indicative of tumors as determined by analyzing tumor DNA, offering better early detection than fecal occult blood tests (FOBT). Based on PCR-technology, ColoAlert® detects more cases of colorectal cancer than other stool tests and allows for an earlier diagnosis (Gies et al., 2018). The product is commercially available in select EU countries through a network of leading independent laboratories, corporate health programs and via direct sales. To receive marketing approval in the US, ColoAlert® will be evaluated in the FDA-registration trial ‘ReconAAsense.’ Once approved in the US, the Company’s commercial strategy is to establish scalable distribution through a collaborative partner program with regional and national laboratory service providers across the country. About Colorectal CancerColorectal cancer (CRC) is the third most common cancer globally, with more than 1.9 million new cases reported in 2020, according to World Cancer Research Fund International. The US Preventive Services Task Force recommends that screening with stool DNA tests such as ColoAlert® should be conducted once every three years starting at age 45. Each year in the US, 16.6 million colonoscopies are performed. However, roughly one-third of US residents aged 50-75 have never been screened for colon cancer. This gap in screening represents a $4.0B+ total market opportunity in the US. About Mainz Biomed NVMainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. ColoAlert® is currently marketed across Europe. The Company is running a pivotal FDA clinical study for US regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test. To learn more, visit mainzbiomed.com or follow us on LinkedIn, Twitter and Facebook. For media inquiries, please contact press@mainzbiomed.com In Europe: MC Services AGAnne Hennecke/Caroline Bergmann+49 211 529252 20mainzbiomed@mc-services.eu In the US: Josh Stanbury+1 416 628 7441josh@sjspr.co For investor inquiries, please contact info@mainzbiomed.com Forward-Looking StatementsCertain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its filings with the SEC, including its annual report on Form 20-F filed on April 7, 2023. The Company’s SEC filings are available publicly on the SEC’s website at sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.